Welcome to our dedicated page for Goodrx Holdings SEC filings (Ticker: GDRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GoodRx Holdings, Inc. (NASDAQ: GDRX) files a range of documents with the U.S. Securities and Exchange Commission that shed light on its operations as a digital healthcare and medication savings platform. These SEC filings include annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K, along with exhibits covering executive compensation, director arrangements, and key commercial developments.
In its earnings-related Form 8-K filings, GoodRx furnishes press releases that discuss revenue from prescription transactions, subscriptions, and pharma manufacturer solutions, as well as non-GAAP metrics such as Adjusted EBITDA and Adjusted Net Income. These documents also describe capital allocation priorities, including investing for growth, debt repayment, share repurchases, and mergers and acquisitions that align with the company’s strategy.
Other 8-K filings provide detail on governance and compensation matters. For example, GoodRx has reported retention bonus agreements for certain executives, including the structure of cash retention bonuses and repayment conditions tied to employment status. It has also disclosed the transition of an executive officer to a non-employee director role, outlining standard non-employee director compensation, committee retainers, and restricted stock unit awards under its non-employee director compensation program and deferred compensation plan.
Through this page, users can access GoodRx’s SEC filings as they are made available via EDGAR. AI-powered summaries on the platform help explain the contents of complex documents, including 10-K and 10-Q reports, by highlighting key themes such as segment performance, prescription transactions trends, subscription and pharma manufacturer solutions growth, and risk factor disclosures. Filings related to insider and director compensation, as well as current reports on material events, are also accessible, giving investors and researchers a structured view of how GoodRx manages its business, governance, and financial reporting obligations.
Spectrum-affiliated investment vehicles reported ownership of a combined 8,905,133 shares of GoodRx Holdings Class A common stock on an as-converted basis, representing 8.28% of outstanding Class A shares. The filing discloses a pro rata distribution by Spectrum Equity VII of 5,983,984 Class A shares to its limited partners and subsequent small open-market sales by two Spectrum funds totaling 16,016 shares for net proceeds of $64,864.80. Individual recordholders include SE VII (8,881,362 shares), Spectrum VII Investment Managers' Fund (15,202 shares) and Spectrum VII Co-Investment Fund (8,569 shares). The filing restates managerial relationships and confirms no reportable transactions in the past 60 days aside from the distribution and the mentioned sales.
GoodRx Holdings, Inc. (GDRX): This Form 4 discloses that on September 4, 2025 Spectrum Equity-related entities converted Class B shares into Class A on a one-for-one basis and distributed 5,983,984 Class A shares pro rata from Spectrum Equity VII, L.P. to its partners for no consideration. Related Spectrum entities also show beneficial ownership changes across multiple funds: Spectrum Equity VII, L.P. reflects 5,983,984 Class A shares acquired and later disposed of on a pro rata basis, while Spectrum VII Investment Managers' Fund and Spectrum VII Co-Investment Fund show smaller acquired amounts (10,243 and 5,773) and subsequent sales at $4.05 per share on September 5, 2025, leaving 0 reported shares for those funds.
GoodRx Holdings, Inc. (GDRX) Form 144 notifies the proposed sale of 10,243 Class A shares through Merrill Lynch on approximately 09/05/2025, with an aggregate market value of $40,972 based on the filing. The shares were acquired on 10/15/2015 in a private placement from the issuer and paid in cash. The filing also discloses closely related sales by affiliated parties during the past three months: Spectrum VII Investment Managers' Fund, LP and Spectrum VII Co-Investment Fund, LP sold multiple tranches of Class A shares on 06/06/2025 and 07/03/2025, totaling 18,354 shares and gross proceeds reported across those trades. The filer certifies no undisclosed material adverse information.
GoodRx Holdings, Inc. (GDRX) submitted a Form 144 notice reporting a proposed sale of 5,773 Class A shares through Merrill Lynch on 09/05/2025, with an aggregate market value of $23,092 and 98,580,674 Class A shares outstanding. The filing states these shares were acquired in a private placement on 10/15/2015 and paid in cash. The notice also lists prior sales by related entities in June and July 2025 totaling 21,354 shares across four transactions with gross proceeds shown for each. The signer certifies no undisclosed material adverse information and references Rule 10b5-1 plan language in the remarks.
Agnes Rey-Giraud transferred 75,219 shares of GoodRx Holdings, Inc. (GDRX) Class A common stock to the ARG Family Legacy Trust #1 on 08/18/2025. The Form 4 shows the Reporting Person serves as sole trustee of the Trust and that members of her family are beneficiaries. After the transaction the filings indicate beneficial ownership entries reflecting the transfer; the Form 4 was signed by an attorney-in-fact on 08/19/2025. The document contains no information about sales, option exercises, or cash consideration beyond the transfer into the Trust.
GoodRx Holdings insider Nabiey Romin reported transactions on 08/15/2025. 4,804 restricted stock units were converted into 4,804 shares of Class A common stock (transaction code M), increasing reported beneficial ownership to 139,011 shares. On the same day a separate sale (transaction code F) disposed of 1,719 shares at $3.54 per share, reducing beneficial ownership to 137,292. The filing shows 67,258 underlying shares remain from outstanding restricted stock units. The RSU vesting schedule is explicit: 6.25% vested May 15, 2025, with the remaining 93.75% vesting in approximately equal quarterly installments over 15 quarters. The form is signed by an attorney-in-fact on behalf of the reporting person.
On 08/08/2025 Nabiey Romin, Chief Accounting Officer of GoodRx Holdings, Inc. (GDRX), reported the vesting of 12,663 restricted stock units (RSUs) and a disposition of 4,531 Class A common shares at a price of $3.47 per share. The Form 4 is signed by Gracye Cheng, Attorney-in-Fact, dated 08/08/2025.
The filing shows beneficial ownership following these transactions of 134,207 Class A shares (direct) and 88,639 derivative securities reported as direct holdings. The RSU disclosure states each unit equals one share, with 6.25% vested on August 8, 2023 and the remaining 93.75% vesting in equal quarterly installments over 15 quarters.